Abstract：
Masticatory myositis (MM) is an inflammatory myopathy reported in dogs and is characterized by inflammation of the masticatory muscles (temporalis, masseter, and pterygoid muscles). Immunosuppressive therapy is the current recommended treatment for MM and may involve glucocorticoids, cyclosporine, azathioprine, mycophenolate mofetil, leflunomide, or a combination of these treatments that are slowly tapered to the lowest effective dose. However, side effects from multimodal medical therapy and complications associated with MM relapses have been reported. The purpose of this case series was to report oclacitinib as a treatment alternative to traditional medical management of MM. The intent of this alternative is to manage side effects from glucocorticoid use. Oclacitinib (1mg/kg per os q12h) was used solely for treatment of MM in three dogs. The dogs were followed up to >6 months after oclacitinib administration. An increase in oral range of motion, as determined by gape angle, was noted in all three dogs. However, a corresponding drop in antibody titers (2M fiber) did not occur. All dogs showed improvement in overall clinical management of MM, side effects from glucocorticoids, and clinical signs related to chronic prednisone use. Larger controlled trials with consistent measurements (interincisal distance, gape angle) and 2M fiber antibody titers are indicated to further assess validation of oclacitinib treatment of MM. The clinical outcome of all dogs was considered successful.
摘要：
咀嚼性肌炎（MM）是一种在狗中报道的炎症性肌病，其特征是咀嚼肌（颞肌，咬肌,和翼状肌）。免疫抑制治疗是目前推荐的MM治疗方法，可能涉及糖皮质激素，环孢菌素,硫唑嘌呤，霉酚酸酯，来氟米特,或这些治疗的组合，慢慢地逐渐减少到最低有效剂量。然而,已经报道了多模式药物治疗的副作用和与MM复发相关的并发症。本病例系列的目的是报告奥拉替尼作为MMM的传统医疗管理的替代治疗方法。该替代方案的目的是控制糖皮质激素使用的副作用。奥克替尼(1mg/kg/osq12h)仅用于治疗三只狗的MM。对狗进行随访直至奥拉替尼给药后>6个月。口腔活动范围的增加，由缺口角度确定，在所有三只狗中都注意到了。然而,抗体滴度（2M纤维）没有相应的下降。所有犬在MM的整体临床管理方面均表现出改善，糖皮质激素的副作用，和慢性使用泼尼松相关的临床症状。具有一致测量值的较大对照试验(切间距离，gapeangle）和2M纤维抗体滴度用于进一步评估奥拉替尼治疗MM的有效性。所有狗的临床结果被认为是成功的。
